January 8, 2018 09:52 AM ESTUpdated 10:06 AM

Shire creates separate neurosciences division for future investments; Agenus gains $28M in royalty deal

Amber Tong

→ Pfizer may be getting out of neurosciences work, but Shire $SHPG is stepping up its game. Shire is creating two separate drug divisions to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Shire creates separate neurosciences division for future investments; Agenus gains $28M in royalty deal

Amber Tong

Sign up to read this article for free.

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Bristol Myers reveals more job cuts in New Jersey

Merck halts Phase 3 trial with PAH drug Winrevair following positive interim data

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Shire cre­ates sep­a­rate neu­ro­sciences di­vi­sion for fu­ture in­vest­ments; Agenus gains $28M in roy­al­ty deal

Amber Tong

Sign up to read this article for free.

more like this

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Bris­tol My­ers re­veals more job cuts in New Jer­sey

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Shire creates separate neurosciences division for future investments; Agenus gains $28M in royalty deal

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Bristol Myers reveals more job cuts in New Jersey

Merck halts Phase 3 trial with PAH drug Winrevair following positive interim data

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA